Cognizant is advancing the application of generative AI (genAI) technology through the NVIDIA BioNeMo platform to help speed up drug discovery in the life sciences industry.
Traditional drug discovery methodologies are process-intensive, entailing the analysis of a huge amount of scientific literature and clinical data to gain relevant insights. They are also costly, time-consuming and have a high rate of failure. By leveraging gen AI technologies, clinical researchers can rapidly sift through extensive datasets, more accurately predict interactions between drug compounds, and create new, viable drug development pathways, says a Cognizant release.
Cognizant collaborates with global firms in the area of pharmaceuticals, biotech and medical devices, across the length of the life sciences value chain — from R&D to digital health. The company said its life sciences offerings support more than 120 global manufacturing lines and 18 million patients.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.